Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 579
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AMG 579 is a potent, selective, and efficacious small molecule inhibitor of phosphodiesterase 10A (PDE10A), with an IC50 of approximately 0.1 nM[1][5]. It was developed by Amgen as a potential antipsychotic for the treatment of schizophrenia and schizoaffective disorder[2][4]. Preclinical studies demonstrated high target occupancy in the brain and efficacy in animal models relevant to psychosis[4]. Clinical development reached phase I trials but was subsequently terminated without further advancement[2][8].
- Other names
- J3.339.633CJ-3.339.633CJ 3.339.633C4-(3-(1-acetylpiperidine-4-yl)pyrazine-2-yloxy)phenyl(1H-benzimidazole-2-yl)methanone
02
Targets
PDE10A (Phosphodiesterase 10A)
Beyond the preview
Go deeper on AMG 579.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 579.